Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway

Basit Öğe Kaydı
dc.contributor.authorDirican, A.
dc.contributor.authorAtmaca, H.
dc.contributor.authorBozkurt, E.
dc.contributor.authorErten, C.
dc.contributor.authorKaraca, B.
dc.contributor.authorUslu, R.
dc.date.accessioned2019-10-27T22:28:23Z
dc.date.available2019-10-27T22:28:23Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractThe treatment of castrate-resistant prostate cancer (CRPC) still remains as an important challenge of daily oncology practice. Docetaxel significantly prolongs overall survival in men with CRPC. Thymoquinone (TQ), one of the flavonoid compounds isolated from Nigealla sativa, has been shown to possess cytotoxic activity against a variety of cancer cell lines. The aim of the study was to investigate the possible synergistic cytotoxic/apoptotic effects of a novel combination, docetaxel and TQ in DU-145 hormone- and drug-refractory prostate cancer cells and their effects on PI3K and ERK signaling pathways. We observed that the combination of docetaxel and TQ resulted in a significant synergistic cytotoxicy and apoptosis as compared to any single agent alone, in a dose-dependent manner. It was found that viability of the combination treated cells was not significantly changed in the presence of LY294002 as compared to inhibitor treated cells. However, in the presence of FR180204, viability of combination treated cells was significantly decreased as compared to inhibitor treated cells. In conclusion, cytotoxic effect of the docetaxel and TQ combination is correlated with the block of the PI3K/Akt signaling pathway in DU-145 cells. Therefore, this combination strategy may be an alternative approach for the challenging era of daily oncologic practice. Also, the combination of docetaxel and TQ might allow a reduction in docetaxel doses and diminish adverse effects of docetaxel while maintaining the therapeutic effect in patients with CRPC.en_US
dc.identifier.doi10.1007/s12094-014-1206-6en_US
dc.identifier.endpage151en_US
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.issue2en_US
dc.identifier.pmid25060568en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org/10.1007/s12094-014-1206-6
dc.identifier.urihttps://hdl.handle.net/11454/50900
dc.identifier.volume17en_US
dc.identifier.wosWOS:000349307800008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofClinical & Translational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectThymoquinoneen_US
dc.subjectDocetaxelen_US
dc.subjectProstate canceren_US
dc.subjectCombination treatmenten_US
dc.subjectPI3K/Akt signaling pathwaysen_US
dc.titleNovel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathwayen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu